Co-Diagnostics Inc (HAM:C970)

Q2 2025 Co-Diagnostics Inc Earnings Call Transcript

Aug 14, 2025 / 08:30 PM GMT

Release Date Price: €6.72 (+2.75%)

Transcript 10-Q8-K

Key Points

Positve

Co-Diagnostics Inc (CODX) is on track to initiate clinical evaluations for all tests in their pipeline during 2025, including the Kodiak PCR COVID-19 test.
The company has received support from reputable organizations such as the National Institute of Health's Radix tech program and the Bill and Melinda Gates Foundation for their test developments.
Co-Diagnostics Inc (CODX) is focusing on increasing the accessibility of affordable, high-quality diagnostics in the United States, India, and globally.
The Kodiak PCR platform is designed to disrupt the current testing paradigm, particularly for tuberculosis, which remains a significant global health challenge.
The company is actively engaging with local health officials and potential customers in India and Africa to evaluate effective commercialization strategies.

Negative

Total revenue for the second quarter of 2025 decreased significantly to $0.2 million compared to $2.7 million in the prior year.
The company reported a net loss of $7.7 million for the second quarter of 2025, slightly higher than the $7.6 million loss in the prior year.
There is uncertainty regarding the timeline for FDA clearance and commercialization of the Kodiak PCR COVID-19 test, which could impact market entry.
The company is reliant on equity and debt financing, as well as grant funding, to meet its capital requirements, indicating potential financial instability.
Despite the progress, there is still a dependency on the successful completion of clinical evaluations and regulatory submissions, which could face unforeseen delays.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CODX.OQ - Co-Diagnostics Inc
Q2 2025 Co-Diagnostics Inc Earnings Call
Aug 14, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to the Co Diagnostics Inc. 2nd quarter 2025 earnings conference call and webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at that time. Simply press star followed by the number one on your telephone keypad and if you would like to withdraw your question again press one.

Thank you. I would now like to turn the conference over to Andrew Benson, head of investor relations. Andrew, the floor is yours.

------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.